About Denovium
Denovium is a Healthcare company based in San Diego (United States) founded in 2018 by Imad Ajjawi, and was acquired by AbSci in January 2021. AI methods and solutions are provided to the biopharma industry. Denovium offers products and services including Integrated Drug Creation Platform, AI Drug Creation, and AI Target Discovery. Its focus areas include Biopharma Outsourcing and Software Development Services. Its legal entity is Absci Corp. Its competitors include Zephyr AI, Transaction Data Systems and OpenEye Scientific; 1 of its 3 listed competitors has raised funding.
Company details
Denovium was founded in 2018 and is based in San Diego, United States. AI-driven methods and solutions are developed for the biopharma sector. Operations focus on applying artificial intelligence to enhance research and development processes in biotechnology and pharmaceuticals. Services include computational tools tailored for drug discovery and data analysis. The company is led by co-founder Imad Ajjawi.
- Headquarters San Diego, United States
- Founders Imad Ajjawi
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website denovium.com
- Social LinkedIn X YouTube
- Acquired by AbSci (Jan 2021)
- Legal Name Absci Corp
Products & Services of Denovium
Denovium offers a comprehensive portfolio of products and services, including Integrated Drug Creation Platform, AI Drug Creation, and AI Target Discovery.
AI platform for designing and optimizing biologics to treat diseases faster
Iterative AI and lab cycles for biologics development and validation
Uses reverse immunology to find novel targets for drug creation
Apps and channels of Denovium
its YouTube channel Absci has 565 subscribers and 15 videos.
Videos from Denovium
The most watched videos on Denovium's YouTube channel, Absci (565 subscribers). Click a video to play it here.
More on Absci.
Investors in Denovium
Denovium has secured backing from 1 investor. Prominent investors backing the company include AbSci.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
AI-based technology is used for recombinant protein production in therapeutics. | 2011 | absci.com | Vancouver, United States |
Investor details for Denovium
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Denovium
29 people are tracked at Denovium (15 in leadership, 5 in board & advisors, 9 in team).
| Name | Role | Group |
|---|---|---|
Imad Ajjawi | Co-Founder | Leadership |
Sean McClain | Founder & CEO | Leadership |
Karin Wierinck | Chief People Officer | Leadership |
Andreas Busch | Chief Innovation Officer | Leadership |
Nikhil Goel | Chief Strategy Officer | Leadership |
Jared Sharp | Associate Director | Leadership |
Michael Mangone | Vice President Of Business Development | Leadership |
Beverly Crider | Director, Alliance Management | Leadership |
Yukte Sharma- Dayal | Sr. Executive Assitant To CEO And CFO | Leadership |
Mario Sanches | Director Of Business Development | Leadership |
Wen Sha | Vp, Chief Of Staff | Leadership |
Chris Ulm | VP, Business Development & Alliance Management | Leadership |
Ben Golomb | Associate Director, Alliance Management & Growth Strategy | Leadership |
Tom Cordaro | Vice President Of Business Development | Leadership |
Chad Taylor | Head Of IT | Leadership |
Zachariah Jonasson | Chairman | Board & advisors |
V. Bryan Lawlis | Director | Board & advisors |
Gustavo Mahler | Director | Board & advisors |
Andy Pihl | Director | Board & advisors |
Dan Gold | Director | Board & advisors |
9 more people are available in the full profile.
Complete people profiles for Denovium
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Denovium
2 dated milestones of Denovium across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Denovium is founded.
- Exit Acquired by AbSci.
Competitors of Denovium
Denovium has 3 listed competitors in our database, 1 of them funded. They include Zephyr AI, Transaction Data Systems and OpenEye Scientific.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| zephyrai.bio | 2020 | United States | $129.85M | Provider of AI development services for biopharma sector | ||
| tdsclinical.com | 1977 | Earth, United States | Software development services are provided to the biopharma sector. | |||
| eyesopen.com | 1997 | Santa Fe, United States | 101 | Drug discovery and design are enabled by a cloud-based platform. |
Detailed competitors of Denovium
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Denovium (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Denovium
Complete news archive for Denovium
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Denovium
Denovium was founded in 2018.
Denovium is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Denovium was founded in 2018 and is based in San Diego, United States. AI-driven methods and solutions are developed for the biopharma sector. Operations focus on applying artificial intelligence to enhance research and development processes in biotechnology and pharmaceuticals. Services include computational tools tailored for drug discovery and data analysis. The company is led by co-founder Imad Ajjawi.
Denovium's top competitors include Zephyr AI, OpenEye Scientific and Transaction Data Systems.
Denovium offers Integrated Drug Creation Platform, AI Drug Creation, and AI Target Discovery.
Denovium has 1 investor. Key investors include AbSci.
Denovium operates through Absci Corp.
Yes. Denovium was acquired by AbSci in January 2021.